Core Thesis - Alphatec Holdings, Inc. (ATEC) presents a bearish investment thesis due to structural headwinds and material downside risks over the next 12 months, particularly following its 4Q'25 results [3][6] Company Overview - ATEC is a medical technology company focused on surgical treatments for spinal disorders, operating both in the United States and internationally [3] Market Dynamics - The company's flagship Prone TransPsoas (PTP) approach to lumbar fusion only addresses a subset of the spinal surgery market, with approximately 19% of fusion-eligible patients unable to use PTP and another 25-33% for whom it is non-ideal [3] - A significant portion of the target population, particularly those with spinal stenosis or herniated discs, either do not require fusion or are better served with decompression procedures, reducing the effective total addressable market to roughly $6 billion, which is about 42% below bullish estimates [4] Regulatory Environment - Regulatory pressures, such as CMS's WISER AI-driven pre-authorization for outpatient fusions, further constrain volumes, especially as outpatient procedures have increased from 2% to 26% of the market [4] Competitive Landscape - Competitor products have achieved technological parity, with ATEC lagging in surgical robotics and overall device functionality, which undermines its previous competitive advantage and limits future case growth [5] - The newly launched Valence robot is considered less capable than offerings from competitors like Medtronic, Globus, and Vista, leading to expectations of slow adoption [5] Financial Outlook - Recent growth in ATEC's sales was largely driven by elevated sales commissions, which are now being normalized, suggesting potential sales rep churn in FY'26 that could threaten surgical volume and market share [5] - Valuation multiples are expected to compress as ATEC faces decelerating sales growth, pricing pressure, and shrinking market opportunities, with a base-case target price of $14.2 indicating approximately 33% downside from current levels [6] - The company is viewed as a high-conviction short with substantial downside potential relative to its current market price [6]

Core Thesis - Alphatec Holdings, Inc. (ATEC) presents a bearish investment case due to structural headwinds and material downside risks over the next 12 months, particularly following its 4Q'25 results [3][6] Company Overview - ATEC is a medical technology company focused on surgical treatments for spinal disorders, operating both in the United States and internationally [3] Market Limitations - The flagship Prone TransPsoas (PTP) approach addresses only a subset of the spinal surgery market, with approximately 19% of fusion-eligible patients unable to use PTP and another 25-33% for whom it is non-ideal [3] - A significant portion of the target population, particularly those with spinal stenosis or herniated discs, either do not require fusion or are better served with decompression procedures, reducing the effective total addressable market to roughly $6 billion, which is about 42% below bullish estimates [4] Regulatory Challenges - Regulatory pressures, such as CMS's WISER AI-driven pre-authorization for outpatient fusions, further constrain volumes, especially as outpatient procedures have increased from 2% to 26% of the market [4] Competitive Landscape - Competitor products have achieved technological parity, with ATEC lagging in surgical robotics and overall device functionality, undermining its previous competitive advantage and limiting future growth [5] - The newly launched Valence robot is considered less capable than offerings from competitors like Medtronic, Globus, and Vista, leading to expectations of slow adoption [5] Sales and Growth Concerns - Recent growth was primarily driven by elevated sales commissions, which are now being normalized, indicating potential sales rep churn in FY'26 that could threaten surgical volume and market share [5] - Valuation multiples are expected to compress as ATEC faces decelerating sales growth, pricing pressure, and shrinking market opportunities, with a base-case target price of $14.2 implying approximately 33% downside from current levels [6]

Group 1 - The company has made significant progress in addressing previous concerns regarding capital deployment, financing, and EBITDA, ending the year with strong cash flows and EBITDA [1] - The first quarter has been volatile for many stocks, particularly in the SMID and small-cap sectors, with Alphatec experiencing similar challenges [2] - There is a notable opportunity within the Spine market, which is large, although the company is currently a small player [2]

Summary of Alphatec FY Conference Call (March 11, 2026) Company Overview - **Company**: Alphatec (NasdaqGS: ATEC) - **Industry**: Spine Surgery and Medical Devices Key Points Market Position and Growth Opportunities - Alphatec has made significant progress in the past year, addressing previous concerns regarding capital deployment, financing, and EBITDA, ending the year with strong cash flows and EBITDA [3][4] - The spine surgery market presents substantial growth opportunities, with Alphatec positioned as a smaller player amidst market share shifts among larger competitors [4][12] - The company believes that improving surgical outcomes through better technology will drive market share growth, as high revision rates in spine surgery indicate room for improvement [9][10] Surgeon Adoption and Utilization Metrics - Surgeon adoption rates have been around 20% over the last eight quarters, with a notable 23% in Q4 [21] - New surgeon users tend to drive mid-double-digit volume growth in subsequent years, indicating a long-term utilization improvement [21] - The average selling price (ASP) for cases is expected to grow at a low single-digit rate, reflecting increased complexity in surgeries as surgeons gain experience with Alphatec's products [22][27] Financial Performance and Cash Flow Management - The company achieved a 41% drop-through to reach approximately 12% adjusted EBITDA last year, with a guidance of 32% drop-through for the current year [64][65] - Effective management of inventory and asset deployment is crucial for supporting growth, with a target of 75 cents on the growth dollar basis [65][66] Competitive Landscape and Rep Dynamics - The competitive environment has been influenced by major players like Stryker and J&J making strategic moves, which has lowered the friction for rep transitions and increased the availability of talent [32][41][45] - The selection of new reps reflects the overall market share dynamics, with no significant over-indexing from any particular competitor [39] Technological Innovations - Alphatec is investing in enabling technologies, such as the Valence robot, which aims to enhance surgical precision and efficiency, particularly in complex procedures [50][58] - The Valence robot is positioned at a competitive price point, making it accessible for both large academic settings and community hospitals [58] Conclusion - Alphatec is confident in its growth trajectory, driven by improved surgeon adoption, innovative technologies, and effective cash flow management strategies. The company is well-positioned to capitalize on the evolving landscape of the spine surgery market [8][12][66]

Group 1 - The analyst team has a proven track record of outperforming across all market conditions with an annualized return of almost 40% over the past decade and a long-only model portfolio return of over 23 times [1] - The focus of the research includes energy, shipping, and offshore markets, indicating a specialization in these sectors [1] - The company offers income-focused picks for investors seeking lower-risk firms with steady dividend payouts [1] Group 2 - The analyst has a historical focus on tech stocks but has expanded coverage to include the offshore drilling and supply industry, as well as the shipping industry [2] - The analyst has experience navigating significant market events, including the dotcom bubble and the subprime crisis, which adds credibility to their insights [2] - The analyst aims to provide high-quality research to the Seeking Alpha community despite language barriers [2]

Alphatec Holdings, Inc. (NASDAQ:ATEC) is one of the best small-cap stocks with huge growth potential. On TD Cowen cut the price target on Alphatec Holdings, Inc. (NASDAQ:ATEC) to $20 from $27 on January 26, maintaining a Buy rating on the shares after a transfer of coverage. The firm sees the company’s “growth vectors” as not being fully appreciated in Street expectations, which creates potential upside to estimates. Alphatec Holdings, Inc. (NASDAQ:ATEC) also received a rating update from Lake Street on ...

Small-cap stocks rarely receive the limelight they deserve. A handful of small-cap companies are quietly laying the groundwork for long-term success. They are expanding market share, improving profitability, and scaling their business models while most investors ignore them for the short-term volatility. With a market cap of $2.07 billion, Alphatec Holdings (ATEC) is one such small-cap stock that investors may regret not buying 10 years from now. More News from Barchart Let’s find out why. www.barchar ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Wednesday.The company reported quarterly earnings of 81 cents per share, which beat the analyst consensus estimate of 77 cents per share. The company reported quarterly sales of $14.438 billion, which beat the analyst consensus estimate of $13.943 billion.HP shares dipped 5.2% to $17.25 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Photo via Shutterstock ...

分组1 - Alphatec reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, compared to a loss of $0.23 per share a year ago, representing an earnings surprise of +50.00% [1] - The company posted revenues of $212.93 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.13%, and this is an increase from year-ago revenues of $176.79 million [2] - Alphatec has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed, losing about 37.5% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is $0.01 on revenues of $201.28 million, and for the current fiscal year, it is $0.24 on revenues of $889.32 million [7] - The Medical - Instruments industry, to which Alphatec belongs, is currently in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - Alphatec reported strong financial performance for Q4 and full-year 2025, highlighting continued share gains in spine surgery and improved profitability, marking its first full year of positive free cash flow [4][7][12] Financial Performance - Q4 total revenue reached $213 million, a 20% increase year-over-year, with surgical revenue at $190 million and EOS revenue at $23 million [3][10] - Full-year 2025 revenue was $764 million, up 25% year-over-year, driven by a 22% increase in procedural volume and a 3% rise in average revenue per procedure [10][11] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a 16% exit margin [6][9] Growth Drivers - Strategic growth initiatives include leadership in lateral procedures, a controlled rollout of the Valence navigation/robotics platform in 2026, and expanded adoption of EOS/EOS Insight to enhance deformity cases [5][13] - The company signed an exclusive partnership with Theradaptive for a future BMP product, expected to enhance its market position [17] Profitability and Cash Flow - Non-GAAP gross margin for Q4 was 70.5%, up 80 basis points year-over-year, attributed to mix, volume leverage, and improved asset efficiency [8] - The company generated $45 million in cash from operations during 2025, resulting in $3 million of free cash flow, marking a transition to a cash-generating business [12] 2026 Outlook - For 2026, Alphatec projects revenue growth of 17% to approximately $890 million, with surgical revenue expected to be around $805 million [18] - Adjusted EBITDA guidance for 2026 is set at $134 million, implying a margin of about 15%, with expectations for non-GAAP gross margin to approach 71% by year-end [18][19]